筛状和导管内癌对基于列线图选择前列腺癌患者行盆腔淋巴结清扫的预测价值
回顾性纳入3家三级转诊中心393例接受根治性前列腺切除术加扩大盆腔淋巴结清扫的前列腺癌患者,外部验证Briganti 2012和MSKCC列线图,并加入活检识别的筛状癌和/或导管内癌(CR/IDC)。加入CR/IDC后两模型拟合改善但AUC未提高,临床风险预测未改善。
要点
- Briganti和MSKCC列线图在临床相关阈值(≤15%)低估淋巴结转移风险。
- 加入CR/IDC后Briganti模型拟合改善(χ2(1)=4.30,P=.04),AUC未提高。
- 加入CR/IDC后MSKCC模型拟合改善(χ2(1)=10.04,P<.01),AUC未提高。
核心结论
- 将CR/IDC纳入两个临床最常用的根治性前列腺切除术前列线图,未改善多国当代前列腺癌队列的淋巴结转移预测。
研究设计与样本
- 回顾性纳入3家三级转诊中心393例接受根治性前列腺切除术加扩大盆腔淋巴结清扫的前列腺癌患者。
- 外部验证Briganti 2012列线图和纪念斯隆凯特琳癌症中心(MSKCC)列线图,并将活检识别的CR/IDC加入两模型。
- 采用似然比检验比较原始模型与CR/IDC更新模型,并通过校准、区分度和临床效用评估预测工具表现。
主要发现
- 109例(28%)男性诊断为淋巴结转移。
- Briganti和MSKCC列线图的校准图显示在临床相关阈值(≤15%)低估淋巴结转移风险。
- 加入CR/IDC后Briganti列线图数据拟合改善(χ2(1)=4.30,P=.04),但AUC未提高(0.69,95%CI 0.63-0.75 vs 0.69,95%CI 0.64-0.75)。
- 加入CR/IDC后MSKCC列线图数据拟合改善(χ2(1)=10.04,P<.01),但AUC未提高(0.66,95%CI 0.60-0.72 vs 0.68,95%CI 0.62-0.74)。
关键数值与推荐
- Briganti列线图加入CR/IDC后AUC为0.69(95%CI 0.63-0.75),未加入CR/IDC时AUC为0.69(95%CI 0.64-0.75)。
- MSKCC列线图加入CR/IDC后AUC为0.66(95%CI 0.60-0.72),未加入CR/IDC时AUC为0.68(95%CI 0.62-0.74)。
- Briganti列线图加入CR/IDC后拟合改善χ2(1)=4.30,P=.04;MSKCC列线图加入CR/IDC后拟合改善χ2(1)=10.04,P<.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the predictive value of biopsy-identified cribriform carcinoma and/or intraductal carcinoma (CR/IDC) within the Briganti and MSKCC nomograms predicting lymph node metastasis (LNM) in patients with primary prostate cancer (PCa). METHODS: We retrospectively included 393 PCa patients who underwent radical prostatectomy with extended pelvic lymph node dissection at 3 tertiary referral centers. We externally validated 2 prediction tools: the Briganti 2012 nomogram and the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram. Both nomograms were augmented with CR/IDC. The original model was compared with the CR/IDC-updated model using the likelihood ratio test. The performance of the prediction tools was assessed using calibration, discrimination, and clinical utility. RESULTS: Overall, 109 (28%) men were diagnosed with LNM. Calibration plots of the Briganti and MSKCC nomograms demonstrated an underestimation of the LNM risk across clinically relevant thresholds (≤15%). The addition of CR/IDC to the Briganti nomogram increased the fit of the data (χ2(1) = 4.30, P = .04), but did not improve the area under the curve (AUC) (0.69, 95% CI 0.63-0.75 vs 0.69, 95% CI 0.64-0.75). Incorporation of CR/IDC in the MSKCC nomogram resulted in an increased fit on the data (χ2(1) = 10.04, P <.01), but did not increase the AUC (0.66, 95% CI 0.60-0.72 vs 0.68, 95% CI 0.62-0.74). The addition of CR/IDC to the Briganti and MSKCC nomograms did not improve the clinical risk prediction. CONCLUSION: Incorporation of CR/IDC into the 2 clinically most used pre-radical prostatectomy nomograms does not improve LNM prediction in a multinational, contemporary PCa cohort.
引用
- de Barros HA, Remmers S, Luiting HB, et al. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology. 2022. PMID: 35803346. doi:10.1016/j.urology.2022.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。